

# Christoffer Gebhardt

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1000733/christoffer-gebhardt-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

78  
papers

4,777  
citations

25  
h-index

69  
g-index

94  
ext. papers

5,929  
ext. citations

6.4  
avg, IF

5.04  
L-index

| #  | Paper  | IF   | Citations |
|----|--|------|-----------|
| 78 | Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. <i>Nature</i> , <b>2017</b> , 547, 222-226  | 50.4 | 1153      |
| 77 | S100A8 and S100A9 in inflammation and cancer. <i>Biochemical Pharmacology</i> , <b>2006</b> , 72, 1622-31  | 6    | 505       |
| 76 | Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 5487-5496   | 12.9 | 373       |
| 75 | RAGE signaling sustains inflammation and promotes tumor development. <i>Journal of Experimental Medicine</i> , <b>2008</b> , 205, 275-85   | 16.6 | 306       |
| 74 | Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 5453-9                                     | 12.9 | 237       |
| 73 | The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression. <i>Vaccines</i> , <b>2016</b> , 4,  | 5.3  | 187       |
| 72 | Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task. <i>European Journal of Cancer</i> , <b>2019</b> , 113, 47-54                                      | 7.5  | 174       |
| 71 | Myeloid cell function in MRP-14 (S100A9) null mice. <i>Molecular and Cellular Biology</i> , <b>2003</b> , 23, 2564-76  | 4.8  | 172       |
| 70 | Endothelial Notch1 Activity Facilitates Metastasis. <i>Cancer Cell</i> , <b>2017</b> , 31, 355-367   | 24.3 | 161       |
| 69 | Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. <i>Immunity</i> , <b>2017</b> , 47, 789-802.e9   | 32.3 | 142       |
| 68 | A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification task. <i>European Journal of Cancer</i> , <b>2019</b> , 111, 148-154 | 7.5  | 115       |
| 67 | Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients. <i>International Journal of Cancer</i> , <b>2015</b> , 136, 2352-60                    | 7.5  | 112       |
| 66 | S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis. <i>Hepatology</i> , <b>2009</b> , 50, 1251-62                                     | 11.2 | 108       |
| 65 | Calgranulins S100A8 and S100A9 are negatively regulated by glucocorticoids in a c-Fos-dependent manner and overexpressed throughout skin carcinogenesis. <i>Oncogene</i> , <b>2002</b> , 21, 4266-76                     | 9.2  | 106       |
| 64 | CCR5 Myeloid-Derived Suppressor Cells Are Enriched and Activated in Melanoma Lesions. <i>Cancer Research</i> , <b>2018</b> , 78, 157-167   | 10.1 | 82        |
| 63 | Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophages. <i>Scientific Reports</i> , <b>2016</b> , 6, 29914   | 4.9  | 70        |
| 62 | CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma. <i>Cancer Immunology, Immunotherapy</i> , <b>2017</b> , 66, 1015-1023  | 7.4  | 56        |

|    |  |      |    |
|----|--|------|----|
| 61 | Profile of gene expression induced by the tumour promotor TPA in murine epithelial cells. <i>International Journal of Cancer</i> , <b>2003</b> , 104, 699-708                                      | 7.5  | 51 |
| 60 | Myeloid-derived suppressor cells and tumor escape from immune surveillance. <i>Seminars in Immunopathology</i> , <b>2017</b> , 39, 295-305   | 12   | 49 |
| 59 | c-Fos-dependent induction of the small ras-related GTPase Rab11a in skin carcinogenesis. <i>American Journal of Pathology</i> , <b>2005</b> , 167, 243-53  | 5.8  | 39 |
| 58 | New therapeutic options for advanced non-resectable malignant melanoma. <i>Advances in Medical Sciences</i> , <b>2015</b> , 60, 83-8   | 2.8  | 37 |
| 57 | Homeostatic nuclear RAGE-ATM interaction is essential for efficient DNA repair. <i>Nucleic Acids Research</i> , <b>2017</b> , 45, 10595-10613  | 20.1 | 37 |
| 56 | Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy. <i>Clinical Chemistry</i> , <b>2018</b> , 64, 830-842 | 5.5  | 34 |
| 55 | Myeloid-derived suppressor cells in malignant melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2014</b> , 12, 1021-7  | 1.2  | 33 |
| 54 | Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target. <i>International Journal of Cancer</i> , <b>2019</b> , 145, 3462-3477     | 7.5  | 28 |
| 53 | Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response. <i>Stem Cell Reports</i> , <b>2017</b> , 8, 1379-1391  | 8    | 25 |
| 52 | Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies <b>2019</b> , 7, 343                    |      | 24 |
| 51 | First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis. <i>Cancer Immunology, Immunotherapy</i> , <b>2019</b> , 68, 765-772                          | 7.4  | 23 |
| 50 | Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma. <i>International Journal of Cancer</i> , <b>2015</b> , 137, 2607-17                              | 7.5  | 22 |
| 49 | Keratinocyte-specific onset of serine protease BSSP expression in experimental carcinogenesis. <i>Journal of Investigative Dermatology</i> , <b>2001</b> , 117, 634-40                             | 4.3  | 22 |
| 48 | TGF- $\beta$ induces SOX2 expression in a time-dependent manner in human melanoma cells. <i>Pigment Cell and Melanoma Research</i> , <b>2016</b> , 29, 453-8                                       | 4.5  | 21 |
| 47 | Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2016</b> , 14, 158-64                 | 1.2  | 19 |
| 46 | Directed Dedifferentiation Using Partial Reprogramming Induces Invasive Phenotype in Melanoma Cells. <i>Stem Cells</i> , <b>2016</b> , 34, 832-46  | 5.8  | 18 |
| 45 | D-dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress. <i>International Journal of Cancer</i> , <b>2017</b> , 140, 914-921                          | 7.5  | 17 |
| 44 | Identification of the RAGE-dependent gene regulatory network in a mouse model of skin inflammation. <i>BMC Genomics</i> , <b>2010</b> , 11, 537  | 4.5  | 17 |

|    |  |      |    |
|----|--|------|----|
| 43 | The shedded ectodomain of Lyve-1 expressed on M2-like tumor-associated macrophages inhibits melanoma cell proliferation. <i>Oncotarget</i> , <b>2017</b> , 8, 103682-103692  | 3.3  | 17 |
| 42 | Predictive immune markers in advanced melanoma patients treated with ipilimumab. <i>Oncolimmunology</i> , <b>2016</b> , 5, e1158901  | 7.2  | 16 |
| 41 | A novel aspartic proteinase-like gene expressed in stratified epithelia and squamous cell carcinoma of the skin. <i>American Journal of Pathology</i> , <b>2006</b> , 168, 1354-64   | 5.8  | 15 |
| 40 | Liquid biopsy to monitor melanoma patients. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2018</b> , 16, 405-414   | 1.2  | 14 |
| 39 | Myeloide Suppressorzellen (MDSC) beim malignen Melanom. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2014</b> , 12, 1021-1027   | 1.2  | 13 |
| 38 | Cutaneous squamous cell carcinoma (cSCC) and immunosurveillance - the impact of immunosuppression on frequency of cSCC. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2019</b> , 33 Suppl 8, 33-37  | 4.6  | 13 |
| 37 | MAP kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma. <i>International Journal of Cancer</i> , <b>2016</b> , 138, 2257-62   | 7.5  | 11 |
| 36 | Pre-analytical factors affecting the establishment of a single tube assay for multiparameter liquid biopsy detection in melanoma patients. <i>Molecular Oncology</i> , <b>2020</b> , 14, 1001-1015                               | 7.9  | 8  |
| 35 | Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia: case report. <i>Medicine (United States)</i> , <b>2014</b> , 93, e161  | 1.8  | 7  |
| 34 | Expression of Neural Crest Markers GLDC and ERFF1 is Correlated with Melanoma Prognosis. <i>Cancers</i> , <b>2019</b> , 11,  | 6.6  | 7  |
| 33 | Sentinel node metastasis mitotic rate (SN-MMR) as a prognostic indicator of rapidly progressing disease in patients with sentinel node-positive melanomas. <i>International Journal of Cancer</i> , <b>2017</b> , 140, 1907-1917 | 7.5  | 6  |
| 32 | STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon- $\gamma$ . <i>Melanoma Research</i> , <b>2018</b> , 28, 204-210   | 3.3  | 6  |
| 31 | Liquid Biopsy zur Berwachung von Melanompatienten. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2018</b> , 16, 405-416  | 1.2  | 6  |
| 30 | The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions. <i>European Journal of Cancer</i> , <b>2020</b> , 138, 68-76  | 7.5  | 6  |
| 29 | The GNAQ in the haystack: intramedullary meningeal melanocytoma of intermediate grade at T9-10 in a 58-year-old woman. <i>Journal of Neurosurgery</i> , <b>2016</b> , 125, 53-6  | 3.2  | 6  |
| 28 | T cell responses in early-stage melanoma patients occur frequently and are not associated with humoral response. <i>Cancer Immunology, Immunotherapy</i> , <b>2015</b> , 64, 1369-81   | 7.4  | 5  |
| 27 | A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for potent melanoma immunotherapy. <i>Annals of Oncology</i> , <b>2017</b> , 28, xi14-xi15                 | 10.3 | 5  |
| 26 | Abstract CT156: A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for immunotherapy of malignant melanoma <b>2018</b> ,                                      |      | 5  |

|    |  |      |   |
|----|--|------|---|
| 25 | Recurrent tattoo reactions in a patient treated with BRAF and MEK inhibitors. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2017</b> , 31, e375-e377  | 4.6  | 4 |
| 24 | Complete remission of treatment-refractory advanced angiosarcoma of the scalp by protracted intralesional interleukin-2 therapy. <i>British Journal of Dermatology</i> , <b>2015</b> , 172, 1156-8   | 4    | 4 |
| 23 | Efficacy of vemurafenib in a trametinib-resistant stage IV melanoma patient--letter. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 2498-9  | 12.9 | 4 |
| 22 | CD74 and CD44 Expression on CTCs in Cancer Patients with Brain Metastasis. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,  | 6.3  | 4 |
| 21 | Extracorporeal Shock Wave Therapy Enhances Receptor for Advanced Glycated End-Product-Dependent Flap Survival and Angiogenesis. <i>Annals of Plastic Surgery</i> , <b>2018</b> , 80, 424-431   | 1.7  | 3 |
| 20 | Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib. <i>Acta Dermato-Venereologica</i> , <b>2015</b> , 95, 96-7  | 2.2  | 3 |
| 19 | Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities.. <i>Cancer Treatment Reviews</i> , <b>2021</b> , 102, 102322  | 14.4 | 3 |
| 18 | Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study. <i>Cellular Immunology</i> , <b>2021</b> , 360, 104274  | 4.4  | 3 |
| 17 | Letter to the Editor: Role of mutational status of GNAQ and GNA11 in the diagnosis of melanocytic tumors. <i>Journal of Neurosurgery</i> , <b>2017</b> , 126, 1024-1026  | 3.2  | 1 |
| 16 | Value of cemiplimab in progressive metastatic cutaneous squamous cell carcinoma after kidney transplantation: a case report. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2022</b> , 36 Suppl 1, 49-52   | 4.6  | 1 |
| 15 | Surveillance of patients with conjunctival melanoma in German-speaking countries: A multinational survey of the German dermatologic cooperative oncology group. <i>European Journal of Cancer</i> , <b>2021</b> , 143, 43-45   | 7.5  | 1 |
| 14 | Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East. <i>International Journal of Cancer</i> , <b>2021</b> , 149, 1926-1934  | 7.5  | 1 |
| 13 | Hyperprogression fortgeschrittener Melanomerkrankung unter Pembrolizumab adjuvant. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2021</b> , 19 Suppl 1, 37-39  | 1.2  | 0 |
| 12 | Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG). <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2021</b> , 147, 1763-1771 | 4.9  | 0 |
| 11 | Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma.. <i>Npj Precision Oncology</i> , <b>2022</b> , 6, 17   | 9.8  | 0 |
| 10 | Multiple epidermotropic melanoma metastases developing during and inhibitor therapy. <i>JAAD Case Reports</i> , <b>2018</b> , 4, 129-131   | 1.4  |   |
| 9  | Standards und Trends bei der Behandlung des malignen Melanoms. <i>Onkopipeline</i> , <b>2009</b> , 2, 101-113  |      |   |
| 8  | Malignes Melanom beim alten und geriatrischen Patienten <b>2018</b> , 527-534  |      |   |

- 7 RAGE ligand S100A8/A9 as a novel prognostic biomarker for high-risk melanoma patients.. *Journal of Clinical Oncology*, **2014**, 32, 9070-9070 2.2
- 6 The GERMELATOX DeCOG-trial: German melanoma patients and their attitude toward toxicity during adjuvant interferon treatment.. *Journal of Clinical Oncology*, **2014**, 32, TPS9113-TPS9113 2.2
- 5 The GERMELATOX DeCOG-trial: Attitude of German melanoma patients towards toxicity during adjuvant interferon treatment Differences between the patient's and the physician's perspective.. *Journal of Clinical Oncology*, **2015**, 33, e20099-e20099 2.2
- 4 Malignes Melanom beim alten und geriatrischen Patienten **2017**, 1-8
- 3 Eignung und Probleme von Serum S100B als Biomarker zur Verlaufskontrolle bei Hochrisiko-Melanompatienten. *JDDG - Journal of the German Society of Dermatology*, **2016**, 14, 158-165 1.2
- 2 Adjuvant pembrolizumab-related hyperprogression in stage III melanoma. *JDDG - Journal of the German Society of Dermatology*, **2021**, 19, 1341-1345 1.2
- 1 Adjuvante Pembrolizumab-assoziierte Hyperprogression eines Melanoms im Stadium III. *JDDG - Journal of the German Society of Dermatology*, **2021**, 19, 1341-1345 1.2